Articles tagged with Clinical Trials
Ludwig scientists will present four clinical trials of checkpoint antibody combination immunotherapies to treat patients with advanced solid tumors, multiple myeloma, and glioblastoma. They will also share findings on other topics, including circulating tumor DNA in early diagnosis and treatment.
A double-blind, placebo-controlled trial tested the 100-year-old drug suramin in boys with autism, showing significant improvements in language, social interactions, and restricted behaviors. The study's findings challenge the conventional view of autism as a fixed, genetically-driven condition and suggest a treatable metabolic syndrome.
UK researchers have made a breakthrough in treating severe lung disease by developing a home ventilation therapy that reduces hospital readmissions. The study, published in the Journal of the American Medical Association, found patients using this treatment were two-thirds less likely to be readmitted within 28 days.
Researchers found that exposure to blue light before competition can improve endurance during a cycling time trial, especially in the final spurt. This effect was observed even if bright light had no impact on overall performance.
A new trial led by Queen's University Belfast aims to improve survival rates for critically ill patients with respiratory failure. The 'extracorporeal carbon dioxide removal' procedure could significantly reduce mortality rates and provide gentler ventilation, reducing lung damage caused by mechanical ventilation.
A phase III trial of 447 patients with biliary tract cancers showed that giving capecitabine after surgery extended survival by a median of 15 months compared to surgery alone. The treatment was associated with a 20% lower chance of death, but the difference was not statistically significant for the overall population.
A phase III clinical trial shows gefitinib is effective in preventing recurrence after lung cancer surgery, with patients going about 10 months longer without disease-free survival. The treatment causes far fewer side effects compared to chemotherapy, with only 12% experiencing severe side effects versus 48%.
A national trial is underway to compare intensive medical management and surgical interventions for asymptomatic carotid artery disease. Researchers at MCG and AU Health are enrolling nearly 2,500 participants in the CREST-2 study to determine which treatment approach reduces stroke risk more effectively.
A new study found that women and minorities undergoing PCI are at higher risk of recurrent cardiac events due to their race, gender, and socioeconomic status. The PLATINUM Diversity trial enrolled a large sample of diverse patients and showed significant differences in adjusted outcomes between groups.
A subgroup analysis of the BRAVO-3 trial found that patients with balloon expandable valves had a different baseline profile than those treated with non-balloon expandable valves. This suggests that differences in patient characteristics, not valve type, drive TAVR outcomes.
The PRECISION trial demonstrated clinical and technical success for patients undergoing robotic percutaneous coronary intervention (PCI) using radial or femoral access. Technical success rates were higher for transradial access procedures, while clinical success rates showed similar outcomes between both approaches.
Positive data from Phase 1 trials of Nexvax2 in celiac disease demonstrate safety, tolerability, and bioactivity. The vaccine reduces gluten-specific T cells' responsiveness to antigenic stimulation without apparent duodenal injury.
A new analysis reveals that early treatment for Non-ST-Elevation Myocardial Infarction (NSTEMI) patients leads to a significant reduction in mortality. The study found an 87% lower mortality rate and a 38% lower mortality rate for high-risk patients when treated within 24 hours of symptom onset.
Patients with new-onset atrial fibrillation post-TAVR have a nearly five-fold greater risk of early stroke compared to those without AF. The BRAVO-3 trial found that patients with existing or new AF had higher rates of pre-existing comorbidities and were more likely to receive oral anticoagulants.
A panel of international experts recommends against knee arthroscopy for almost all patients with degenerative knee disease, citing limited evidence of long-term pain relief and function improvement. Non-use of knee arthroscopy can be used as a performance measure to reduce unnecessary surgery.
A mock randomized control trial across three countries found that eating red Smarties had no effect on participants' levels of happiness. This study debunks the common assumption that red is associated with feelings of happiness and demonstrates how complex scientific concepts can be made engaging through hands-on learning.
A phase 1 pilot study is examining the feasibility and safety of administering a second T-cell product to increase the long-term persistence of CAR T cells. The goal is to reduce the relapse rate, which is currently around 50%.
A new study investigates the use of oxygen therapy via high-flow nasal tubes in patients with COPD experiencing exacerbations. The short-term trial found lower retained carbon dioxide levels compared to standard oxygen therapy, suggesting a potential benefit.
The RICMAC trial found that dose-reduced conditioning followed by allogeneic stem cell transplantation improved overall and relapse-free survival for patients with myelodysplastic syndrome. Engraftment rates were comparable between the two groups, with higher non-relapse mortality after standard conditioning.
A large randomized controlled trial found that acupuncture significantly improved the quality of life and physical and mental health of patients with allergic asthma. The study involved 1445 participants who received on average 15 acupuncture sessions over three months, with benefits maintained for up to six months.
A randomized clinical trial of 100 obese adults found that alternate-day fasting resulted in similar weight loss to daily calorie restriction (5.3% vs 6.0%). The study suggests that daily calorie restriction may be a more effective option for weight maintenance and cardiovascular disease risk reduction.
A randomized clinical trial found that ivabradine did not improve outcomes in patients with heart failure with preserved ejection fraction. Elevated heart rate is a predictive factor of worse outcomes in these patients, contradicting previous research that suggested benefits for heart failure with reduced ejection fraction.
Serelaxin, a hormone with vasodilatory effects, failed to improve cardiovascular outcomes in the phase 3 RELAX-AHF-2 trial. Despite initial promising results from previous studies, serelaxin showed no significant benefit in reducing worsening heart failure or all-cause mortality.
A global trial of 20,000 women in 21 countries found that tranexamic acid reduces death due to bleeding after childbirth by a third if given within 3 hours. The drug is inexpensive and widely available, making it a promising solution for preventing maternal deaths in low-income countries.
A study published in PLOS ONE found that shortening standard consent documents did not affect comprehension, but early delivery and in-person explanations improved it. Concise forms showed promise in streamlining ethics committee reviews, but further testing is needed.
Several emerging companies are developing innovative neuromodulation therapies to alleviate conditions such as autism spectrum disorder, spinal cord injury, and persistent pain. BioInduction Ltd.'s Picostim and BlueWind Medical's RENOVA iStim aim to provide targeted stimulation for various clinical indications.
A new test evaluates sperm's capacitation ability, allowing for more accurate diagnoses of male infertility. The Cap-Score Sperm Function Test shows promise in increasing conception rates among men with unexplained infertility.
The SARAH trial found SIRT resulted in higher tumor response rates and controlled tumor progression compared to sorafenib, with better side-effect profiles and quality of life scores. However, it did not increase overall survival in HCC patients.
The American Society of Clinical Oncology will host its 53rd Annual Meeting, featuring more than 2,150 abstracts on various cancer topics. The meeting highlights recent breakthroughs in immunotherapy and precision medicine, with a focus on improving patient care and outcomes.
Researchers developed a prognostic tool predicting end-stage renal disease risk in type 1 and 2 diabetes patients. The test uses biomarker values to identify those at high risk, improving the efficiency and cost-effectiveness of clinical trials.
A collaboration created a 3D-printed phantom of a stenotic intracranial artery to standardize high-resolution MRI protocols for studying intracranial atherosclerotic disease. The phantom enables standardized vessel-wall MRI at multiple sites, facilitating multicenter trials and accelerating research.
A recent study led by the University of Nottingham found that wearing silk clothing does not reduce the severity of eczema in children with moderate to severe eczema. The study involved recruiting hospitals across the UK and assessed the effectiveness of specialist silk garments against standard treatment.
The pivotal MOMENTUM 3 trial found that patients with the new HeartMate 3 LVAS experienced fewer adverse clotting and bleeding events than those with the control device, HeartMate II. The study also developed a novel scoring system to quantify these events.
A clinical trial found that twice-weekly yoga led to better physical, sexual, emotional, and social health in men with prostate cancer. Patients who practiced yoga reported lower fatigue and improved urinary function compared to those without yoga.
A large randomized trial found that monthly high-dose vitamin D supplementation does not reduce cardiovascular disease risk. The study, published in JAMA Cardiology, involved 2558 adults with low vitamin D levels and showed no significant difference in cardiovascular events between the treatment and placebo groups.
A recent study found that multivitamin supplements did not reduce the risk of cardiovascular disease in middle-aged and older men, regardless of their initial dietary intake or nutritional status. The Physicians' Health Study II, a large-scale randomized clinical trial, investigated this potential benefit over an 11-year period.
A new triple inhaler has shown a 20% reduction in chronic obstructive pulmonary disease (COPD) flare-ups in a year-long trial involving 2,691 patients. The study found that the inhaler improved lung function and reduced symptoms, with potential benefits for early diagnosis and targeted treatment.
A Phase 2 clinical trial found that MLE4901 reduced the number and severity of hot flushes by 73% compared to placebo. The treatment was well-tolerated, with no serious adverse events reported. This study demonstrates the potential for MLE4901 as a non-hormonal treatment option for menopausal hot flushes.
A randomized clinical trial will compare surgery and non-operative therapy for patients with rotator cuff tears, considering factors such as age and tear size. The study aims to inform patient care and provide evidence-based information for better health decisions.
A new research project aims to integrate socio-economic data with cancer trial data, providing a broader perspective on treatment effectiveness. By combining this information, researchers can predict how socio-economic factors affect various treatments and shed light on the circumstances of cancer patients in clinical trials.
A Phase 2/2b clinical trial has begun testing an experimental DNA vaccine designed to protect against disease caused by Zika infection. The vaccine aims to gain more safety and immune response data and determine if it can effectively prevent disease caused by natural Zika infection.
The University of Miami is conducting a multi-site study to evaluate the safety, effective dosage and prevention capabilities of the NIH's experimental DNA-based vaccine. Researchers will recruit individuals from Miami-Dade County and compare the rates of confirmed cases of Zika in vaccinated and placebo groups.
A study found that higher doses of vitamin C, particularly 8g per day, significantly reduced the duration of common cold symptoms. The findings suggest a dose-dependent effect and could lead to improved treatment options for individuals with common colds.
A molecule called polyGP accumulates in the CSF and blood cells of patients with C9ORF72 ALS, offering a potential pharmacodynamic marker for therapeutic responses. Detection of polyGP in asymptomatic carriers may help identify patients at risk before symptoms appear.
A leading dementia expert emphasizes the importance of cognitive rehabilitation for people with dementia, sharing similarities with physical rehabilitation. Rehabilitation aims to enable individuals to participate meaningfully in everyday life and family/family activities.
Researchers compiled a list of over 40 online programs with evidence from randomized controlled trials, finding nearly 80% were unavailable to the public. The sites address various health issues, including depression, weight loss, and chronic pain, and offer interactive modules and assignments to complete.
A three-year research collaboration aims to create more accurate ways of measuring cancer progression. The project uses digital images from completed clinical trials to develop drug response metrics, with the goal of identifying optimal tumor burden measurement methods.
A network of clinical trials aims to find the right treatment for the right patient, using individual molecular profiles. The project will recruit 658 patients across the UK, with a focus on matching patients with suitable clinical trials already in progress.
A study found that midazolam was more effective in treating seizures than other benzodiazepines and was adopted by ambulances across the country, increasing from 26.1% to 61.7% between 2010 and 2014. The rate of adoption accelerated after a clinical trial's publication, with EMS agencies adopting midazolam at a rate of 8.9% per year.
A Phase I clinical trial demonstrates the safety of transplanting autologous Schwann cells into a spinal cord lesion, showing no negative effects after 1 year. The study successfully determined safety and feasibility for performing peripheral nerve harvests within 5-30 days followed by intra-spinal transplantation within 4-7 weeks.
A new protocol has been shown to be safe and effective in assessing older people who have fallen. The guidelines reduce further 999 calls and left fewer people without continuing care after their fall by 11%.
Researchers found that a single dose of millions of adult stem cells can aid stroke recovery if given early, reducing destructive inflammation and the risk for serious infections. Early treatment within 36 hours after stroke symptoms surface also showed benefits in physical recovery and reduced disability one year out.
Researchers found that a pacemaker delivering a pacing program designed to detect and stop abnormal heart rhythms can significantly reduce fainting episodes in patients with recurrent syncope. The study, known as SPAIN, showed a seven-fold reduction in recurrences of syncope in patients who used the program.
A recent study found that Embol-X and CardioGard devices did not significantly reduce overall number of brain infarcts during aortic valve replacement, but may affect size. However, patients treated with these devices experienced reduced delirium after surgery. Further research is needed to clarify potential health outcomes.
The SURTAVI trial shows that self-expanding TAVR is non-inferior to open-heart surgery for intermediate-risk patients with severe aortic stenosis, with comparable rates of stroke and death. The study found no significant differences in mortality or disabling stroke between the two groups at 2 years.
The SURTAVI trial shows that TAVR is comparable to surgical aortic valve replacement for intermediate-risk patients, with similar all-cause mortality rates and better mean aortic valve gradient at two years. Near-term results also indicate improved outcomes for TAVR patients, including lower stroke rates and quicker hospital discharge.
A new standard of care has been established worldwide for treating prostate cancer, reducing treatment duration to four weeks without compromising outcomes. The trial found that this compressed regimen resulted in slightly fewer side effects and improved quality of life for participants.
A Florida clinic's unproven stem cell treatment blinded three women with macular degeneration, causing vision loss and other complications. The treatment, which involved injecting fat cells into the eyes, lacked proper scientific design and oversight.
A meta-analysis of three randomized trials found that vitamin E supplementation reduced the risk of contrast medium-induced acute kidney injury (CIAKI) by up to 62%. This may be due to its antioxidant activity, with a pooled effect indicating significant protection against CIAKI.
Researchers discovered that many breast cancer patients have mutational signatures similar to those with faulty BRCA1 or BRCA2 genes, suggesting they may also benefit from existing PARP inhibitor treatments. This opens up the possibility of treating up to 20% of women with these drugs.